The Company VOC Diagnostics AB Our vision To reduce mortality globally, increase quality of life and reduce patient care costs by enabling a paradigm shift in early diagnosis of cancer. Value proposition Provide an easy and reliable analysis method that can detect cancer at an early stage with high accuracy

The Product (OC detect) An electronic nose with inspiration from man’s best friend Ability to detect VOCs specific for ovarian cancer from blood 100% sensitivity and 97.5% specificity in double-blind tests OC Detect Patented electronic nose for detection and diagnosis of ovarian cancer from blood Gas sensors to detect volatile organic compounds (VOCs) emitted by cancer tumors Advanced SW algorithm and statistical analysis 92% sensitivity and 93% specificity showed in a published clinical study on 165 bloodsamples.(Horvath et al, J Cancer Sci Ther, Dec 2018)

Business case: Targeting a potential multi-billion market Market for ovarian cancer diagnostics in € Europe United states Diagnosis Test volume 1 500 000 (nr of tests) 1 000 000 (nr of tests) Price (€/test) 50 Market value 75 MIO 50 MIO Early detection on symptoms 6 000 000 4 000 000 25 150 MIO 100 MIO Screening 38 000 000 24 000 000 10 380 MIO 240 MIO Note: Prices are specified for specific total volumes for given scenarios, not dependent on uses at particular time. I.e. the price is assumed to be the same at given time regardless of used for diagnosis or screening